{Reference Type}: Case Reports
{Title}: Lisdexamfetamine dimesylate (Vyvanse) toxicosis in a dog.
{Author}: Martindale DM;Haraschak JL;Thiel AJ;Samuelson JP;Buchweitz JP;
{Journal}: J Vet Emerg Crit Care (San Antonio)
{Volume}: 34
{Issue}: 2
{Year}: 2024 Mar-Apr 27
{Factor}: 1.693
{DOI}: 10.1111/vec.13370
{Abstract}: <B>OBJECTIVE: </B>To describe the presentation, management, and postmortem examination findings in a dog with confirmed lisdexamfetamine dimesylate (LDX) toxicosis.<BR><B>METHODS: </B>A 3-year-old female neutered mixed breed dog initially presented with neurological signs suspected to be secondary to LDX toxicosis. The dog was treated as typical for amphetamine toxicoses but developed severe respiratory and cardiovascular signs throughout their hospitalization. The progression of the cardiopulmonary signs led to cardiopulmonary arrest, for which CPR was unsuccessful. Postmortem examination exhibited severe hemorrhage throughout multiple organ systems. Toxicology testing confirmed the presence of unaltered LDX and its metabolite, amphetamine.<BR><B>CONCLUSIONS: </B>This is the first case report documenting a severe progression of clinical signs and postmortem examination findings in a case of confirmed LDX toxicosis in a dog. Although the patient did not survive treatment, postmortem examination and microscopic evaluation of tissues allowed visualization of the extent of systemic pathophysiology. With prompt treatment, the prognosis of amphetamine toxicosis in dogs is generally considered good; however, this case report demonstrates a severe case in which even prompt and appropriate treatment did not prevent mortality. This suggests a need to establish negative prognostic indicators for which to monitor in cases of amphetamine toxicosis. Finally, this report is also unique in the fact that the LDX toxicosis was confirmed using a toxicological analysis technique not previously described clinically in dogs.